Overall survival analysis showed that TNFAIP6, IFITM2, IFNGR1, and IRF6 expression levels were not significant, whereas IFRD1 (n = 568) indicated a significantly (p < 0.05) increased risk in Luminal A breast cancer patients, along with NFIL3 (n = 219) in Luminal B patients with similar significance. This evidence concerns the gene IRF6 and breast carcinoma.